However, transfusion therapy and the increased uptake of iron caused by the disease lead to iron deposition in various organs, which can lead to life-threatening complications. Therefore, the administration of iron-binding medication is also part of the treatment. Zynteglo TM (former name: LentiGlobin TM ) is a gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have a β0/β0 genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available. Zynteglo TM is bluebird bio's first gene therapy to gain regulatory approval. "We are proud to be the commercial manufacturing partner of bluebird bio and to be part of bringing this life-changing therapy to TDT patients in Europe", commented Dr. Christine Günther, CEO of apceth Biopharma.